Free tool
FAERS Monitor: Wakix
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 211150 or its brand name (Wakix, Pitolisant Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
2,117
Serious
1,013
48% of reports
Hospitalization
247
Death reported
10
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nausea245
- drug ineffective239
- anxiety235
- headache222
- insomnia221
- product administration interrupted203
- somnolence190
- product dose omission issue186
- fatigue184
- dizziness125
- middle insomnia125
- depression116
- surgery113
- feeling abnormal103
- vomiting97
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2015 | 7 |
| 2016 | 17 |
| 2017 | 7 |
| 2018 | 20 |
| 2019 | 39 |
| 2020 | 496 |
| 2021 | 158 |
| 2022 | 240 |
| 2023 | 294 |
| 2024 | 444 |
| 2025 | 272 |
| 2026 | 123 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,042 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product administration interruptedSignal | 203 | 263.7 | 231.0 | 51,525 |
| middle insomniaSignal | 125 | 67.0 | 56.5 | 8,009 |
| surgerySignal | 113 | 19.2 | 16.0 | 1,931 |
| somnolenceSignal | 190 | 9.4 | 8.2 | 1,427 |
| insomniaSignal | 221 | 8.2 | 7.3 | 1,418 |
| anxietySignal | 235 | 8.2 | 7.3 | 1,500 |
| product dose omission issueSignal | 186 | 6.3 | 5.5 | 833 |
| depressionSignal | 116 | 5.1 | 4.2 | 379 |
| feeling abnormalSignal | 103 | 4.3 | 3.5 | 258 |
| headacheSignal | 222 | 3.5 | 3.1 | 410 |
| nauseaSignal | 245 | 3.1 | 2.7 | 354 |
| dizzinessSignal | 125 | 2.5 | 2.1 | 113 |
| fatigueSignal | 184 | 2.3 | 2.0 | 146 |
| vomitingSignal | 97 | 2.0 | 1.7 | 52 |
| drug ineffective | 239 | 1.8 | 1.6 | 90 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.